American Gene Technologies International Inc. (AGT)

A private biotechnology company developing cures and treatments
for Infectious diseases, cancers and monogenic disorders.

Corporate Profile

AGT, has a broad, robust lentiviral delivery platform evolved over ten years of advanced development. AGT has an extensive and growing patent portfolio surrounding its lentiviral platform innovations that accelerate the development of a wide variety of drug candidates. This platform allows AGT to pursue exciting clinical “cures” in large and orphan indications and complex diseases. AGT’s proprietary platform technologies provide reusable components that allow AGT and its internationally recognized collaborators to create new therapies in a fraction of the time of traditional drug development processes and other drug companies. AGT is expecting to begin clinical trials this year for an HIV cure based on a successful pre-IND meetings with the FDA.

AGT has built a rich product pipeline of genetic therapies for patients suffering from infectious disease, monogenic disorders, and cancer, using its lentiviral vector platform and patented methods.

Scientists Explain the Science

Scientific & Clinical Advisors

Pipeline

USPTO Patents & FDA Designation

AGT’s patent portfolio protects its technology platform and methods. In addition to below, AGT has several patents pending and over 20 patent families represented by filings with the USPTO and international patent offices. Also, AGT has been granted FDA Orphan Drug Designation for its treatment of Phenylketonuria (PKU).

Newsletters

Press Releases

Load More (27)

Media

E-mail Alerts & Newsletter

Sign-up to receive AGT's latest financial news & events.

MailChimp Sidebar Investor Page

Latest AGT Tweets